TWI820266B - 巨環化合物及其用途 - Google Patents

巨環化合物及其用途 Download PDF

Info

Publication number
TWI820266B
TWI820266B TW108144324A TW108144324A TWI820266B TW I820266 B TWI820266 B TW I820266B TW 108144324 A TW108144324 A TW 108144324A TW 108144324 A TW108144324 A TW 108144324A TW I820266 B TWI820266 B TW I820266B
Authority
TW
Taiwan
Prior art keywords
methyl
group
ring
cr4r5
ethyl acetate
Prior art date
Application number
TW108144324A
Other languages
English (en)
Chinese (zh)
Other versions
TW202039494A (zh
Inventor
松本重充
原亮磨
野口直義
福士英人
新居田歩
佐佐木聡
生駒実
小林俊威
前川毅志
Original Assignee
日商思可海雅藥品股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70975488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI820266(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商思可海雅藥品股份有限公司 filed Critical 日商思可海雅藥品股份有限公司
Publication of TW202039494A publication Critical patent/TW202039494A/zh
Application granted granted Critical
Publication of TWI820266B publication Critical patent/TWI820266B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW108144324A 2018-12-05 2019-12-04 巨環化合物及其用途 TWI820266B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-228234 2018-12-05
JP2018228234 2018-12-05

Publications (2)

Publication Number Publication Date
TW202039494A TW202039494A (zh) 2020-11-01
TWI820266B true TWI820266B (zh) 2023-11-01

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108144324A TWI820266B (zh) 2018-12-05 2019-12-04 巨環化合物及其用途

Country Status (18)

Country Link
US (1) US11518763B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890738A4 (cg-RX-API-DMAC7.html)
JP (2) JP7895177B2 (cg-RX-API-DMAC7.html)
KR (1) KR102919982B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164468A (cg-RX-API-DMAC7.html)
AR (1) AR117251A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391942B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010704A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121952C (cg-RX-API-DMAC7.html)
CL (1) CL2021001451A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007304A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006527A (cg-RX-API-DMAC7.html)
NZ (1) NZ776102A (cg-RX-API-DMAC7.html)
PH (1) PH12021551262A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105125XA (cg-RX-API-DMAC7.html)
TW (1) TWI820266B (cg-RX-API-DMAC7.html)
UA (1) UA127872C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020116660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
BR112023004567A2 (pt) * 2020-09-14 2023-04-04 Sanofi Sa Derivados de tetrahidroisoquinolina para o tratamento de doenças do sangue e doenças inflamatórias
AU2024251986A1 (en) * 2023-04-03 2025-10-16 Acelink Therapeutics, Inc. Novel compounds and uses thereof
CN119707895B (zh) * 2023-12-18 2026-03-31 江苏苏中药业研究院有限公司 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法
WO2026026967A1 (zh) * 2024-08-02 2026-02-05 劲方医药科技(上海)股份有限公司 丙烯酰基类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092713A1 (en) * 2013-12-18 2015-06-25 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
WO2017026516A1 (ja) 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
EP3573963B1 (en) 2017-01-30 2021-09-01 Biogen MA Inc. Nrf2 activator
US20190389836A1 (en) * 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092713A1 (en) * 2013-12-18 2015-06-25 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
MX2021006527A (es) 2021-07-21
UA127872C2 (uk) 2024-01-31
KR20210099622A (ko) 2021-08-12
EP3890738A1 (en) 2021-10-13
WO2020116660A1 (en) 2020-06-11
SG11202105125XA (en) 2021-06-29
JP7895177B2 (ja) 2026-07-27
CA3121952A1 (en) 2020-06-11
CO2021007304A2 (es) 2021-06-21
AR117251A1 (es) 2021-07-21
US11518763B2 (en) 2022-12-06
JP2024123202A (ja) 2024-09-10
EP3890738A4 (en) 2022-08-17
CN113164468A (zh) 2021-07-23
TW202039494A (zh) 2020-11-01
BR112021010704A2 (pt) 2021-08-24
CL2021001451A1 (es) 2021-12-24
PH12021551262A1 (en) 2021-10-25
US20220119391A1 (en) 2022-04-21
AU2019391942B2 (en) 2024-03-21
KR102919982B1 (ko) 2026-02-02
AU2019391942A1 (en) 2021-06-03
CA3121952C (en) 2025-05-13
JP2022510736A (ja) 2022-01-27
NZ776102A (en) 2024-12-20

Similar Documents

Publication Publication Date Title
ES3060188T3 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
US11518763B2 (en) Macrocyclic compound and use thereof
TWI856956B (zh) 人類整合素α4β7拮抗劑
TWI476190B (zh) C型肝炎病毒抑制劑
TWI789381B (zh) 雜環化合物
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
WO2002053534A1 (en) Vla-4 inhibitors
IL304110B2 (en) Inhibitors of keap1-nrf2 protein-protein interaction
WO2018181345A1 (ja) 複素環化合物
CA3081424A1 (en) Spirocyclic compounds as farnesoid x receptor modulators
SK7602002A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
KR20200083529A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
CA3018275A1 (en) Benzo[b]furans as bromodomain inhibitors
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
RU2798235C9 (ru) Макроциклическое соединение и его применение
RU2798235C2 (ru) Макроциклическое соединение и его применение
JP7449300B2 (ja) ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
CA3129619A1 (en) Substituted amide compounds useful as farnesoid x receptor modulators
TW202537962A (zh) 抑制α-V β-1整合素
KR20260005897A (ko) 신규 화합물 및 이의 용도
HK1263406B (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
HK1263406A1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors